JP2004517882A - トリプトライドプロドラッグを使用する抗癌処置 - Google Patents

トリプトライドプロドラッグを使用する抗癌処置 Download PDF

Info

Publication number
JP2004517882A
JP2004517882A JP2002557346A JP2002557346A JP2004517882A JP 2004517882 A JP2004517882 A JP 2004517882A JP 2002557346 A JP2002557346 A JP 2002557346A JP 2002557346 A JP2002557346 A JP 2002557346A JP 2004517882 A JP2004517882 A JP 2004517882A
Authority
JP
Japan
Prior art keywords
group
triptolide
alkyl
treatment
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002557346A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004517882A5 (enExample
Inventor
ジョン エム． フィルダー，
ケ リ，
Original Assignee
ファーマジェネシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマジェネシス， インコーポレイテッド filed Critical ファーマジェネシス， インコーポレイテッド
Publication of JP2004517882A publication Critical patent/JP2004517882A/ja
Publication of JP2004517882A5 publication Critical patent/JP2004517882A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
JP2002557346A 2001-01-19 2002-01-18 トリプトライドプロドラッグを使用する抗癌処置 Pending JP2004517882A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/766,156 US6620843B2 (en) 2001-01-19 2001-01-19 Anticancer treatment using triptolide prodrugs
PCT/US2002/001650 WO2002056835A2 (en) 2001-01-19 2002-01-18 Anticancer treatment using triptolide prodrugs

Publications (2)

Publication Number Publication Date
JP2004517882A true JP2004517882A (ja) 2004-06-17
JP2004517882A5 JP2004517882A5 (enExample) 2006-02-02

Family

ID=25075572

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002557346A Pending JP2004517882A (ja) 2001-01-19 2002-01-18 トリプトライドプロドラッグを使用する抗癌処置

Country Status (8)

Country Link
US (1) US6620843B2 (enExample)
EP (1) EP1359909B1 (enExample)
JP (1) JP2004517882A (enExample)
AT (1) ATE406155T1 (enExample)
AU (1) AU2002237884B2 (enExample)
CA (1) CA2435322A1 (enExample)
DE (1) DE60228544D1 (enExample)
WO (1) WO2002056835A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503831A (ja) * 2002-09-18 2006-02-02 成都▲達▼▲遠▼▲薬▼物有限公司 高免疫抑制活性の水溶性トリプトリド誘導体及びその応用
JP2012526148A (ja) * 2009-05-07 2012-10-25 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ トリプトリド製品

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7847109B2 (en) * 2002-05-31 2010-12-07 Pharmagenesis, Inc. Triptolide derivatives for modulation of apoptosis and immunosuppression
JP2006513209A (ja) * 2002-12-17 2006-04-20 ファーマジェネシス， インコーポレイテッド 免疫調節因子および抗癌剤としてのトリプトライド誘導体
US6943259B2 (en) * 2003-02-25 2005-09-13 Pharmagenesis, Inc. Halogenated triptolide derivatives as immunomodulators and anticancer agents
WO2005062913A2 (en) * 2003-12-24 2005-07-14 Pharmagenesis, Inc. Triplide 5,6-derivatives as immunomodulators and anticancer agents
EP1722806A4 (en) * 2004-02-09 2009-09-16 Pharmagenesis Inc METHOD OF ISOLATING TRIPTOLIDE COMPOUNDS FROM TRIPTERYGIUM WILFORDII
CN100558354C (zh) * 2004-03-02 2009-11-11 美国泛华医药公司 用作免疫调节药和抗癌药的雷公藤内酯醇内酯环衍生物
WO2006012204A2 (en) * 2004-06-25 2006-02-02 Pharmagenesis, Inc. Method for treatment of inflammatory disorders using triptolide compounds
WO2006044496A2 (en) * 2004-10-13 2006-04-27 Pharmagenesis, Inc. Identification and screening of triptolide target molecules
EP1946758A1 (en) * 2007-01-18 2008-07-23 Pierre Fabre Medicament Treatment of acute myeloid leukemia
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
CN104387406A (zh) * 2009-02-05 2015-03-04 药物起源公司 作为抗癌药和免疫调制剂的雷公藤内酯 c-环衍生物
US9150600B2 (en) 2009-05-07 2015-10-06 Regents Of The University Of Minnesota Triptolide prodrugs
WO2011127291A2 (en) * 2010-04-07 2011-10-13 Caritas St. Elizabeth Medical Center Of Boston, Inc. Compositions and methods for the treatment of a neoplasia
US9846160B2 (en) 2012-02-27 2017-12-19 Board Of Regents, The University Of Texas Systems Ganglioside GD2 as a marker and target on cancer stem cells
CA3013619A1 (en) * 2016-02-04 2017-08-10 The Johns Hopkins University Glucose conjugates of triptolide, analogs and uses thereof
CN107698653B (zh) * 2017-10-11 2019-08-27 中国农业科学院蜜蜂研究所 一种雷公藤甲素半抗原及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005108A (en) 1973-04-03 1977-01-25 Research Corporation Novel anti-leukemic diterpenoid triepoxides
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5663335A (en) 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US5962516A (en) 1997-02-28 1999-10-05 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US6548537B1 (en) * 1998-09-02 2003-04-15 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility
EP1109789B1 (en) * 1998-09-02 2003-07-16 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility
US6294546B1 (en) * 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
EP1390358A4 (en) * 2001-03-15 2004-06-16 Pharmagenesis Inc AMINO ACID DERIVATIVES OF TRIPTOLIDE COMPOUNDS AS IMMUNOMODULATORS AND ANTICROPHES

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503831A (ja) * 2002-09-18 2006-02-02 成都▲達▼▲遠▼▲薬▼物有限公司 高免疫抑制活性の水溶性トリプトリド誘導体及びその応用
JP2012526148A (ja) * 2009-05-07 2012-10-25 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ トリプトリド製品

Also Published As

Publication number Publication date
EP1359909A4 (en) 2005-03-09
CA2435322A1 (en) 2002-07-25
US6620843B2 (en) 2003-09-16
WO2002056835A3 (en) 2003-02-27
WO2002056835A2 (en) 2002-07-25
ATE406155T1 (de) 2008-09-15
AU2002237884B2 (en) 2006-08-17
EP1359909B1 (en) 2008-08-27
DE60228544D1 (de) 2008-10-09
US20020099051A1 (en) 2002-07-25
EP1359909A2 (en) 2003-11-12

Similar Documents

Publication Publication Date Title
US6620843B2 (en) Anticancer treatment using triptolide prodrugs
AU2002237884A1 (en) Anticancer treatment using triptolide prodrugs
US6302838B1 (en) Cancer treatment with epothilones
US5225404A (en) Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
JP6005855B2 (ja) 血管破壊薬および低酸素を標的とする薬剤を含む併用療法
JP5087052B2 (ja) 改良された治療剤
AU2927999A (en) Use of epothilones for the treatment of cancer
CN100406013C (zh) 喜树碱衍生物
JP2001247459A (ja) 癌の組み合わせ療法
JP2010270124A (ja) 抗癌組み合わせ
JP2018188432A (ja) 抗腫瘍化合物
CN107921005A (zh) 利用纳米颗粒治疗肿瘤的组合物和方法
EP2254570B1 (en) Combination comprising paclitaxel for treating ovarian cancer
ES2385850T3 (es) Potenciador de radioterapia
JP2014534238A (ja) 癌を治療するためのビス（チオヒドラジドアミド）化合物の投与
JP2006070032A (ja) 抗血管形成薬剤組成物
WO2020062951A1 (zh) 化合物及其用途
US9937261B2 (en) Combination therapy comprising a liposomal prodrug of mitomycin C and radiotherapy
ES2330324T3 (es) Derivados del epotilon para el tratamiento del hepatoma y de otros canceres.
WO2008124823A1 (en) Method of treating melanoma
JP4780834B2 (ja) 新規なプテリン抗新生物薬
CN104080449A (zh) 4，9-二羟基-萘并[2，3-b]呋喃脂肪酸酯衍生物的纳米颗粒水悬液的制备方法
JP2010526073A (ja) 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体
JP5891168B2 (ja) 腫瘍を処置するための医薬的組合せ
KR20210150470A (ko) A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080703

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080929

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081031

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090226